Competent psychopharmacology

Canadian Journal of Psychiatry

Volumn 59, Issue 8, 2014, Pages 406-411

  Gardner, David M ^a,b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Antidepressant; Antipsychotic; Competency; Continuing education; Mental illness; Patient experience; Post graduate education; Prescribing; Psychiatry; Psychotropics

Indexed keywords

PSYCHOTROPIC AGENT;

CLINICAL COMPETENCE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEALTH CARE QUALITY; HUMAN; MEDICAL EDUCATION; MEDICAL PRACTICE; MEDICAL STUDENT; PATIENT ASSESSMENT; PATIENT EDUCATION; PRESCRIPTION; PSYCHOPHARMACOLOGY; RECURRENT DISEASE; REVIEW; TREATMENT RESPONSE;

CANADA; CLINICAL COMPETENCE; COOPERATIVE BEHAVIOR; CURRICULUM; EDUCATION, MEDICAL, CONTINUING; EDUCATION, NURSING, CONTINUING; EDUCATION, PHARMACY, CONTINUING; HUMANS; INTERDISCIPLINARY COMMUNICATION; OFF-LABEL USE; PATIENT EDUCATION AS TOPIC; PSYCHOPHARMACOLOGY; PSYCHOTROPIC DRUGS;

EID: 84905974633     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674371405900802     Document Type: Review

References (55)

1. Hyman SE. Revitalizing psychiatric therapeutics. Neuropsychopharmacology. 2014;39(1):220-229.
2. Taylor MA. Hippocrates cried: the decline of American psychiatry. Oxford (GB): Oxford University Press; 2013.
3. Stettin GD, Yao J, Verbrugge RR, et al. Frequency of follow-up care for adult and pediatric patients during initiation of antidepressant therapy. Am J Manag Care. 2006;12(8):453-461. (Pubitemid 44267083)
4. Chen SY, Hansen RA, Farley JF, et al. Follow-up visits by provider specialty for patients with major depressive disorder initiating antidepressant treatment. Psychiatr Serv. 2010;61(1):81-85.
5. Olfson M, Marcus SC, Weissman MM, et al. National trends in the use of psychotropic medications by children. J Am Acad Child Adolesc Psychiatry. 2002;41(5):514-521. (Pubitemid 38338129)
6. Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2012 National Survey on Drug Use and Health: mental health findings, NSDUH series H-47, HHS publication no (SMA) 13-4805. Rockville (MD): SAMHSA; 2013.
7. Baldessarini RJ. Chemotherapy in psychiatry: pharmacologic basis of treatments for major mental illness. 3rd ed. New York (NY): Springer; 2013.
8. Gardner DM, Teehan MD. Antipsychotics and their side effects. Cambridge (GB): Cambridge University Press; 2010.
9. Barker WA, Scott J, Eccleston D. The Newcastle chronic depression study: results of a treatment regime. Int Clin Psychopharmacol. 1987;2(3):261-272.
10. Sadock BJ, Sadock VA, Ruiz P, et al. Kaplan and Sadock's comprehensive textbook of psychiatry. 9th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2009.
11. Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci. 2011;6:42.
12. Olfson M, Blanco C, Wang S, et al. National trends in the mental health care of children, adolescents, and adults by office-based physicians. JAMA Psychiatry. 2014;71(1):81-90.
13. Olfson M, Kroenke K, Wang S, et al. Trends in office-based mental health care provided by psychiatrists and primary care physicians. J Clin Psychiatry. 2014;75(3):247-253.
14. Midlov P, Bondesson A, Eriksson T, et al. Effects of educational outreach visits on prescribing of benzodiazepines and antipsychotic drugs to elderly patients in primary health care in southern Sweden. Fam Pract. 2006;23(1):60-64.
15. Keijsers CJ, Van Hensbergen L, Jacobs L, et al. Geriatric pharmacology and pharmacotherapy education for health professionals and students: a systematic review. Br J Clin Pharmacol. 2012;74(5):762-773.
16. Kamarudin G, Penm J, Chaar B, et al. Educational interventions to improve prescribing competency: a systematic review. BMJ Open. 2013;3(8):e003291.
17. Driesen A, Verbeke K, Simoens S, et al. International trends in lifelong learning for pharmacists. Am J Pharm Educ. 2007;71(3):52.
18. Fleury MJ, Imboua A, Aube D, et al. General practitioners' management of mental disorders: a rewarding practice with considerable obstacles. BMC Fam Pract. 2012;13(1):19.
19. Forsetlund L, Bjorndal A, Rashidian A, et al. Continuing education meetings and workshops: effects on professional practice and health care outcomes. Cochrane Database Syst Rev. 2009;(2):CD003030.
20. Davis D, Davis N. Selecting educational interventions for knowledge translation. CMAJ. 2010;182(2):E89-E93.
21. Davis DA, Prescott J, Fordis CM Jr, et al. Rethinking CME: an imperative for academic medicine and faculty development. Acad Med. 2011;86(4):468-473.
22. Merkur S, Mossialos E, Long M, et al. Physician revalidation in Europe. Clin Med. 2008;8(4):371-376.
23. Ahmed K, Wang TT, Ashrafian H, et al. The effectiveness of continuing medical education for specialist recertification. Can Urol Assoc J. 2013;7(7-8):266-272.
24. Knopp RK, Wyer PC. Maintenance of certification: a work in progress. Ann Emerg Med. 2014;63(4):471-473.e2.
25. Vázquez GH. The impact of psychopharmacology on contemporary clinical psychiarty. Can J Psychiatry. 2014;59(8):412-416.
26. Baldessarini RJ. The impact of psychopharmacology on contemporary psychiatry. Can J Psychiatry. 2014;59(8):401-405.
27. Marcus SC, Olfson M. National trends in the treatment for depression from 1998 to 2007. Arch Gen Psychiatry. 2010;67(12):1265-1273.
28. Shrank WH, Polinski JM, Avorn J. Quality indicators for medication use in vulnerable elders. J Am Geriatr Soc. 2007;55(Suppl 2):S373-S382. (Pubitemid 47515348)
29. Sultzer DL, Davis SM, Tariot PN, et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry. 2008;165(7):844-854. (Pubitemid 351948716)
30. Barbui C, Signoretti A, Mule S, et al. Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophr Bull. 2009;35(2):458-468.
31. Correll CU, Rummel-Kluge C, Corves C, et al. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull. 2009;35(2):443-457.
32. Morrow RL, Garland EJ, Wright JM, et al. Influence of relative age on diagnosis and treatment of attention-deficit/hyperactivity disorder in children. CMAJ. 2012;184(7):755-762.
33. Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302(16):1765-1773.
34. Medicaid Medical Directors Learning Network (MMDLN) and Rutgers Center for Education and Research on Mental Health Therapeutics (CERTS). Antipsychotic medication use in Medicaid children and adolescents: report and resource guide from a 16-state study. MMDLN-Rutgers CERTs publication no 1 [Internet]. New Brunswick (NJ): Distributed by Rutgers CERTs; 2010 Jul [cited 2014 Apr 14]. Available from: http://rci.rutgers.edu/~cseap/MMDLNAPKIDS.html. Further details can be found at: http://chsr.rutgers.edu/MMDLNAPKIDS.html.
35. Patten SB, Waheed W, Bresee L. A review of pharmacoepidemiologic studies of antipsychotic use in children and adolescents. Can J Psychiatry. 2012;57(12):717-721.
36. Olfson M, Blanco C, Liu SM, et al. National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry. 2012;69(12):1247-1256.
37. Birnbaum ML, Saito E, Gerhard T, et al. Pharmacoepidemiology of antipsychotic use in youth with ADHD: trends and clinical implications. Curr Psychiatry Rep. 2013;15(8):382.
38. Bobo WV, Cooper WO, Stein CM, et al. Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry. 2013;70(10):1067- 1075.
39. Murphy AL, Gardner DM, Cooke C, et al. Prescribing trends of antipsychotics in youth receiving income assistance: results from a retrospective population database study. BMC Psychiatry. 2013;13(1):198.
40. Parry PI, Levin EC. Pediatric bipolar disorder in an era of "mindless psychiatry". J Trauma Dissociation. 2012;13(1):51-68.
41. Pringsheim T, Gardner DM. Dispensed prescriptions for quetiapine and other second-generation antipsychotics in Canada from 2005 to 2012: a descriptive study. CMAJ Open. Forthcoming 2014.
42. Klein-Schwartz W, Schwartz EK, Anderson BD. Evaluation of quetiapine abuse and misuse reported to poison centers. J Addict Med. 2014;8(3)195-198. Epub ahead of print.
43. Sawa T. Prisoners given powerful drugs off-label, allegedly to 'control behaviour' [Internet]. Toronto (ON): Canadian Broadcasting Corporation; 2014 [cited 2014 Apr 16]. Available from: http://www.cbc.ca/news/prisoners-given- powerful-drugs-off-label-allegedly-to-control-behaviour-1.2609940.
44. Bobo WV, Epstein RA Jr, Hayes RM, et al. The effect of regulatory advisories on maternal antidepressant prescribing, 1995-2007: an interrupted time series study of 228,876 pregnancies. Arch Womens Ment Health. 2014;17(1):17-26.
45. Epstein RA, Bobo WV, Shelton RC, et al. Increasing use of atypical antipsychotics and anticonvulsants during pregnancy. Pharmacoepidemiol Drug Saf. 2013;22(7):794-801.
46. Benkert O, Graf-Morgenstern M, Hillert A, et al. Public opinion on psychotropic drugs: an analysis of the factors influencing acceptance or rejection. J Nerv Ment Dis. 1997;185(3):151-158. (Pubitemid 27508667)
47. Van Schaik DJ, Klijn AF, Van Hout HP, et al. Patients' preferences in the treatment of depressive disorder in primary care. Gen Hosp Psychiatry. 2004;26(3):184-189. (Pubitemid 38581923)
48. Appelbaum PS, Gold A. Psychiatrists' relationships with industry: the principal-agent problem. Harv Rev Psychiatry. 2010;18(5):255-265.
49. Cosgrove L, Krimsky S. A comparison of DSM-IV and DSM-5 panel members' financial associations with industry: a pernicious problem persists. PLOS Med. 2012;9(3):e1001190.
50. Gardner DM, Murphy AL, Woodman A, et al. Community pharmacy services for antidepressant users. Int J Pharm Pract. 2001;9:217-224. (Pubitemid 34038323)
51. Demyttenaere K. Risk factors and predictors of compliance in depression. Eur Neuropsychopharmacol. 2003;13(Suppl 3):S69-S75. (Pubitemid 37188777)
52. Maddox JC, Levi M, Thompson C. The compliance with antidepressants in general practice. J Psychopharmacol. 1994;8(1):48-52.
53. Bull SA, Hu XH, Hunkeler EM, et al. Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA. 2002;288(11):1403-1409. (Pubitemid 35025915)
54. Murphy A, Gardner D, Kutcher S, et al. Collaborating with youth to inform and develop tools for psychotropic decision making. J Can Acad Child Adolesc Psychiatry. 2010;19(4):256-263.
55. Medication Infoshare [Internet]. Halifax (NS): Medication Infoshare; 2014 [cited 2014 Apr 26]. Available from: http://medicationinfoshare.com.